Patent · US Active

Compounds and methods of treating retinal degeneration

US11191752B2 · kind B2 · utility

2Cited by
1References
18Claims
0Family size

Assignees

Inventors

Key dates

Filing dateApr 30, 2018
Grant dateDec 7, 2021
Priority date
Expiry dateMay 10, 2038

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P29/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This application relates to compounds and methods of treating retinal degeneration associated with inherited rhodopsin mutations in the ocular tissue of a subject. The retinal degeneration, can include, for example, macular degeneration, a including age-related macular degeneration, Stargardt disease, and retinitis pigmentosa. The retinitis pigmentosa can include autosomal dominate retinitis pigmentosa associated with a P23H RHO mutation. A method of treating retinal degeneration in a subject includes administering to the subject a therapeutically effective amount of a compound of formula (I), wherein the compound of formula (I) acts as a chaperone of rhodopsin.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.